Section Arrow
CDTX.NASDAQ
- Cidara Therapeutics
Quotes are at least 15-min delayed:2025/11/15 01:29 EST
Regular Hours
Last
 217.71
+111.72 (+105.41%)
Day High 
218.85 
Prev. Close
105.99 
1-M High
116.15 
Volume 
17.29M 
Bid
216.01
Ask
217.75
Day Low
216.8 
Open
217.2 
1-M Low
93 
Market Cap 
3.33B 
Currency USD 
P/E -- 
%Yield -- 
10-SMA 103.81 
20-SMA 102.54 
50-SMA 92.51 
52-W High 121.21 
52-W Low 14.33 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-11.22/-4.54
Enterprise Value
3.33B
Balance Sheet
Book Value Per Share
13.44
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
1.28M
Operating Revenue Per Share
1.80
Industry Comparison
Code Name   Last Change Change (%) P/E P/E Range
ASBPAspire Biopharma Holdings Inc.0.1063+0.0011+1.05%-- 
CYPHCypherpunk Technologies Inc.2.75+0.99+56.25%-- 
IVVDInvivyd2.35+0.58+32.77%-- 
APLTApplied Therapeutics0.2183-0.0517-19.15%-- 
RXRXRecursion Pharmaceuticals4.14-0.19-4.39%-- 
Quotes are at least 15-min delayed:2025/11/15 01:29 EST
Industry overview quotes are at least 15 minutes delayed
Business Description
Cidara Therapeutics Inc is developing immunotherapeutics designed to help improve the standard of care for patients facing serious diseases. Its clinical-stage asset is CD388, a DFC intended for influenza prophylaxis. The Company's portfolio comprises new approaches aimed at transforming existing treatment and prevention paradigms, including DFCs from its proprietary Cloudbreak platform targeting oncologic, viral and autoimmune diseases.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.